Renal cell carcinoma (RCC) accounts for 2%--3% of all malignant diseases in adults \[[@b1-jptm-2018-09-21]\]. Clear cell renal cell carcinoma (ccRCC) is the most common renal tumor subtype and is closely associated with von Hippel Lindau (*VHL*) tumor suppressor gene mutations that lead to the stabilization of hypoxia-inducible factors in both sporadic and familial forms. Recently, three tumor suppressor gene mutations, namely, *PBRM1*, *SETD2*, and *BAP1*, located close to *VHL* on chromosome 3p were reported \[[@b2-jptm-2018-09-21]-[@b4-jptm-2018-09-21]\].

Studies have reported *BAP1* mutation in about 10%--15% of ccRCC cases \[[@b5-jptm-2018-09-21],[@b6-jptm-2018-09-21]\]. BRCA1-associated protein 1 (BAP1) is a nuclearlocalized deubiquitinating enzyme that was initially discovered as a BRCA1-associated protein and known to interact with multiple proteins. BAP1 was shown to exhibit a tumor suppressor role in several cancers through its deubiquitinase activity, thereby regulating target gene transcription, cell cycle control, DNA damage repair, and cellular differentiation \[[@b7-jptm-2018-09-21]\]. Inactivation mutations of the *BAP1* gene, including insertion, deletion, frameshift, nonsense, and missense mutations, have also been reported \[[@b8-jptm-2018-09-21]\].

The germline mutation in the *BAP1* gene is inherited in an autosomal dominant pattern \[[@b9-jptm-2018-09-21]\]. Affected individuals inherit a nonfunctional *BAP1* allele, as observed with other tumor suppressors, and the remaining functional allele is inactivated later in life. There is a high risk for developing tumors, including atypical Spitz tumors, uveal melanoma, cutaneous melanoma, epithelioid malignant mesothelioma, and ccRCC \[[@b10-jptm-2018-09-21]\]. *BAP1* germline mutations are associated with poor prognosis in uveal melanoma, cutaneous melanoma, and ccRCC \[[@b10-jptm-2018-09-21]\]. Sporadic *BAP1* mutations have also been identified in several tumors, including uveal melanoma \[[@b11-jptm-2018-09-21]\], malignant mesothelioma \[[@b12-jptm-2018-09-21]\], and ccRCC. The loss of *BAP1* expression in mesothelial cells in effusion cytology specimens is an indicator of possible mesothelioma \[[@b13-jptm-2018-09-21]\]. Nearly half of the investigated uveal melanoma tumors harbor an inactivating *BAP1* mutation, which was strongly associated with the loss of BAP1 nuclear staining and other aggressive prognostic features \[[@b14-jptm-2018-09-21]\]. Furthermore, several studies have revealed the association between inactivating *BAP1* mutation and high grade ccRCC \[[@b6-jptm-2018-09-21]\], sarcomatoid transformation, and poor prognosis in patients with ccRCC \[[@b15-jptm-2018-09-21]\], especially in those with low-grade RCC \[[@b16-jptm-2018-09-21]\]. The loss of BAP1 expression in immunohistochemical staining has been reported as a highly reliable method for the detection of *BAP1* mutation \[[@b6-jptm-2018-09-21]\]. Although *BAP1* mutations are frequently observed in ccRCC, limited data are available on the expression of BAP1 in other RCC types.

Therefore, we evaluated the loss of BAP1 nuclear expression in several subtypes of RCC, including ccRCC, papillary RCC, and chromophobe RCC, and analyzed its relationship with clinicopathological characteristics of patients.

MATERIALS AND METHODS
=====================

Patient selection
-----------------

A total of 371 samples were retrospectively obtained from Hanyang University Hospital (247 cases, 2005--2017) and Soonchunhyang University Bucheon Hospital (124 cases, 2001--2013). Formalin-fixed, paraffin-embedded tissue samples obtained from surgically resected primary tumors at the time of initial diagnosis were collected. The pathologist in each institution reviewed the slides and selected a representative block for each case, and 3.0 mm of core tissue microarray (TMA) blocks were constructed, with two representative cores for each case. The patient and tumor characteristics, including age, type of surgery, histological type, histological grade, and follow-up data, were acquired. The histological subtypes were classified according to the 2016 World Health Organization (WHO) Tumor Classification. We graded ccRCC and papillary RCC according to the 2013 WHO/International Society of Urological Pathology (ISUP) grading system \[[@b17-jptm-2018-09-21],[@b18-jptm-2018-09-21]\]. Chromophobe RCC was graded according to the published parameters \[[@b19-jptm-2018-09-21]\]. All cases were reviewed by two pathologists for tumor type and WHO/ISUP grade. This study was approved by the Institutional Review Board of the Hanyang University Hospital (HYUH 2018-05-005), and the requirement for informed consent was waived.

Immunohistochemistry for BAP1 expression
----------------------------------------

Sections from the TMA blocks were immunostained using the Bond-max Automated immunohistochemistry (IHC)/*in situ* hybridization stainer (Leica Biosystems, Nussloch, Germany) according to the manufacturer's protocol. Sections (4-μm thickness) were immunostained with a primary antibody against BAP1 (1:100, sc-28383, mouse monoclonal, Santa Cruz Biotechnology, Santa Cruz, CA, USA). BAP1 expression level was evaluated according to the extent of nuclear staining in the tumor cells. The staining was scored as negative (no expression or expression in \< 10% of tumor cells) or positive (expression in ≥ 10% of tumor cells).

Statistical analysis
--------------------

All of the statistical analyses were performed using SPSS ver. 24.0 (IBM Corp., Armonk, NY, USA). The relationships between the groups were compared using the chi-square test, Fisher exact test, or Student's t test. Cancer-specific survival (CSS) was defined as the time interval between the date of surgical resection and the date of death due to RCC. Recurrence-free survival (RFS) was defined as the time interval between surgical resection and the date of any recurrence. The Kaplan-Meier method with the log-rank test and the Cox proportional hazard regression model were used for survival analyses. Two-sided p-values of \< .05 were considered to indicate statistically significant differences.

RESULTS
=======

Patient characteristics
-----------------------

The clinicopathological characteristics of the patients are summarized in [Table 1](#t1-jptm-2018-09-21){ref-type="table"}. Among 371 RCC cases, the most common subtype was ccRCC (300 cases, 80.9%). The other subtypes included in this study comprised 36 cases of papillary RCC (13 type 1 and 23 type 2 papillary RCC, 9.7%), 26 cases of chromophobe RCC (7.0%), four cases of clear cell papillary RCC, four cases of acquired cystic disease-associated RCC, and one case of collecting duct carcinoma. The age of the patients ranged from 13 to 90 years, with a median of 60 years. The median follow-up period for the patients in this study was 66 months (range, 0.1 to 167.6 months). Of the 371 patients, 11 (3.0%) had metastatic disease at the time of initial diagnosis (i.e., nephrectomy), 30 (8.1%) had experienced metastasis or relapse during the follow-up period, and 34 (9.2%) had died due to RCC by the time of analysis.

BAP1 expression and tumor type evaluation
-----------------------------------------

A total of 371 successfully stained cases with adequate clinical follow-up were classified as either BAP1 negative (n = 63, 17.0%) or BAP1 positive (n = 308, 83.0%). Representative images of BAP1 staining are shown in [Fig. 1](#f1-jptm-2018-09-21){ref-type="fig"}. Loss of BAP1 expression was frequently observed in ccRCC (18.7%) and chromophobe RCC (23.1%), while we failed to observe BAP1 expression loss in other renal tumor subtypes, including papillary RCC, acquired cystic disease-associated RCC, and collecting duct carcinoma. In clear cell papillary RCC, one case showed loss of BAP1 expression ([Table 2](#t2-jptm-2018-09-21){ref-type="table"}).

BAP1 expression and clinicopathological features of patients with ccRCC and chromophobe RCC
-------------------------------------------------------------------------------------------

In ccRCC, loss of BAP1 expression was significantly associated with female sex (p = .046) and high WHO/ISUP grade (p = .002). Furthermore, BAP1 expression loss was more frequent in pT2 than in pT1 category ([Table 3](#t3-jptm-2018-09-21){ref-type="table"}). Other clinicopathological parameters such as vascular invasion, tumor necrosis, sarcomatoid feature, and lymph node status showed no significant association with BAP1 expression ([Table 3](#t3-jptm-2018-09-21){ref-type="table"}).

In chromophobe RCC, no significant correlation was observed between BAP1 expression and clinicopathological parameters ([Table 3](#t3-jptm-2018-09-21){ref-type="table"}).

BAP1 expression and survival in ccRCC
-------------------------------------

Of 300 patients with ccRCC, 10 (3.3%) had metastatic disease at the time of initial diagnosis (i.e., nephrectomy), 23 (7.7%) had experienced metastasis or relapse during the follow-up period, and 26 (8.7%) had died due to RCC by the time of analysis.

Kaplan-Meier analysis and Cox regression analysis were applied to evaluate the prognostic value of BAP1 loss. Univariate analysis revealed that high WHO/ISUP grade, vascular invasion, tumor necrosis, sarcomatoid feature, high pT category, and lymph node metastasis predicted a poor outcome in ccRCC ([Table 4](#t4-jptm-2018-09-21){ref-type="table"}). However, BAP1 expression showed no association with CSS and RFS ([Fig. 2A](#f2-jptm-2018-09-21){ref-type="fig"}, [B](#f2-jptm-2018-09-21){ref-type="fig"}). Even in cases with low pT (pT1/2) ccRCC, loss of BAP1 expression showed no statistically significant correlation with CSS and RFS ([Fig. 2C](#f2-jptm-2018-09-21){ref-type="fig"}, [D](#f2-jptm-2018-09-21){ref-type="fig"}).

DISCUSSION
==========

In this study, we demonstrated the loss of BAP1 nuclear expression in chromophobe RCC and clear cell papillary RCC as well as ccRCC. Furthermore, the loss of BAP1 nuclear expression was associated with adverse clinicopathological features such as high WHO/ISUP grade in ccRCC but showed no relationship with CSS or RFS in patients with ccRCC.

The Cancer Genome Atlas (TCGA) research network recently reported the molecular characterization of RCC and included 488 ccRCC, 160 papillary type 1 RCC, 70 papillary type 2 RCC, and 81 chromophobe RCC. *BAP1* mutation, a chromatin remodeling gene mutation, was reported in ccRCC (11.0%) and papillary RCC (5.6%) but not in chromophobe RCC \[[@b20-jptm-2018-09-21]\]. *BAP1* mutation was also shown to be correlated with decreased survival in ccRCC \[[@b20-jptm-2018-09-21]\].

The ratio of BAP1 loss in the present study (18.7%) was similar to that reported in previous studies \[[@b21-jptm-2018-09-21],[@b22-jptm-2018-09-21]\]. We also found that the loss of BAP1 expression was significantly common in female sex (p = .046). *BAP1* mutation was more frequent in female patients as per TCGA data \[[@b20-jptm-2018-09-21],[@b23-jptm-2018-09-21]\]. We observed that BAP1 nuclear expression loss was associated with high WHO/ISUP grade in ccRCC and showed no correlation with CSS and RFS. In several studies, loss of BAP1 expression served as an independent marker of prognosis in patients with ccRCC and low-grade ccRCC \[[@b24-jptm-2018-09-21],[@b25-jptm-2018-09-21]\]. On the other hand, in other studies, no significant association was reported between BAP1 loss and CSS or RFS, although BAP1 loss significantly correlated with poor clinicopathological parameters \[[@b16-jptm-2018-09-21],[@b21-jptm-2018-09-21]\]. Differences in the prognostic associations may be related to differences in cohorts among studies. Our cohort had relatively low-grade RCC and a short follow-up period; therefore, overall cancer-specific death rate was lower than that recorded in the previous TGCA report (8% vs 33%) \[[@b20-jptm-2018-09-21]\].

Among non-ccRCC, papillary RCC, chromophobe RCC, clear cell papillary RCC, acquired cystic disease-associated RCC, and collecting duct carcinoma were evaluated for BAP1 expression. We observed the loss of BAP1 expression in 23.1% of chromophobe RCC (6/26) cases and in one clear cell papillary RCC case. No significant association was detected between BAP1 expression and adverse clinicopathological parameters in chromophobe RCC. Unfortunately, the number of patients with chromophobe RCC and clear cell papillary RCC was too small to evaluate proper clinical relevance. In addition, during the follow-up period, one patient died due to chromophobe RCC; therefore, survival analysis could not be performed. An additional analysis is needed to further elucidate the role of BAP1 and the relationship between loss of BAP1 expression in IHC and *BAP1* mutation in chromophobe RCC and clear cell papillary RCC.

In conclusion, we revealed that BAP1 expression is associated with high WHO/ISUP grade in patients with ccRCC and that BAP1 expression loss is also observed in chromophobe RCC and clear cell papillary RCC. Further studies are needed to assess larger cohorts and associated pathological features.
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###### 

Histological and clinical characteristics

  Characteristic                                                       Value (n = 371)
  -------------------------------------------------------------------- -----------------
  Tumor type                                                           
   Clear cell RCC                                                      300 (80.9)
   Chromophobe RCC                                                     26 (7.0)
   Papillary RCC, type 1                                               13 (3.5)
   Papillary RCC, type 2                                               23 (6.2)
   Others                                                              9 (2.4)
  Age (yr)                                                             60.0 (13--90)
  Sex                                                                  
   Male                                                                246 (66.3)
   Female                                                              125 (33.7)
  Tumor size                                                           3.77 (0.7--15)
  WHO/ISUP grade (clear and papillary RCC)                             
   1                                                                   33 (9.8)
   2                                                                   160 (47.6)
   3                                                                   113 (33.6)
   4                                                                   30 (8.9)
  Chromophobe grade (chromophobe RCC)                                  
   1                                                                   19 (73.1)
   2                                                                   7 (26.9)
  Vascular invasion^[a](#tfn1-jptm-2018-09-21){ref-type="table-fn"}^   
   Absent                                                              323 (87.1)
   Present                                                             48 (12.9)
  Tumor necrosis                                                       
   Absent                                                              219 (84.2)
   Present                                                             41 (15.8)
  Sarcomatoid feature                                                  
   Absent                                                              350 (94.3)
   Present                                                             21 (5.7)
  Lymph node metastasis                                                
   Absent                                                              362 (97.6)
   Present                                                             9 (2.4)
  pT category                                                          
   1                                                                   258 (69.5)
   2                                                                   36 (9.7)
   3                                                                   74 (19.9)
   4                                                                   3 (0.8)

Values are presented as number (%) or median (range).

RCC, renal cell carcinoma; WHO, World Health Organization; ISUP, International Society of Urological Pathology.

Vascular invasion includes microscopic tumor invasion into small or large vessels and gross renal vein tumor thrombus.

###### 

Correlation between BAP1 expression and tumor type (n = 371)

                                           Negative (n = 63)   Positive (n = 308)
  ---------------------------------------- ------------------- --------------------
  Clear cell RCC                           56 (18.7)           244 (81.3)
  Chromophobe RCC                          6 (23.1)            20 (76.9)
  Papillary RCC type 1                     0                   13 (100)
  Papillary RCC type 2                     0                   23 (100)
  Clear cell papillary RCC                 1 (25)              3 (75)
  Acquired cystic disease-associated RCC   0                   4 (100)
  Collecting duct carcinoma                0                   1 (100)

Values are presented as number (%).

BAP1, BRCA1-associated protein 1; RCC, renal cell carcinoma.

###### 

Correlations between BAP1 expression and clinicopathological features

                                                                 Clear cell RCC (n = 300)   Chromophobe RCC (n = 26)                                 
  -------------------------------------------------------------- -------------------------- -------------------------- ------ ---------- ----------- ---------
  Sex                                                                                                                  .046                          .664
   Male                                                          32 (15.6)                  173 (84.4)                        3 (27.3)   8 (72.7)    
   Female                                                        24 (25.3)                  71 (74.7)                         3 (20.0)   12 (80.0)   
  WHO/ISUP grade                                                                                                       .002                          
   1                                                             0                          25 (100)                                                 
   2                                                             20 (14.1)                  122 (85.9)                                               
   3                                                             27 (25.7)                  78 (74.3)                                                
   4                                                             9 (32.1)                   19 (67.9)                                                
  Chromophobe grade                                                                                                                                  .146
   1                                                                                                                          6 (31.6)   13 (68.4)   
   2                                                                                                                          0          7 (100)     
  Vascular invasion                                                                                                    .664                          .231
   Absent                                                        49 (19.1)                  203 (80.9)                        5 (20.0)   20 (80.0)   
   Present                                                       7 (16.3)                   36 (83.7)                         1 (100)    0           
  Tumor necrosis                                                                                                       .437                          
   Absent                                                        28 (16.8)                  139 (83.2)                        6 (23.1)   20 (76.9)   
   Present                                                       8 (22.2)                   28 (77.7)                                                
  Sarcomatoid feature                                                                                                  .346                          
   Absent                                                        51 (18.1)                  231 (81.9)                        6 (23.1)   20 (76.9)   
   Present                                                       5 (27.8)                   13 (72.2)                                                
  pT category^[a](#tfn2-jptm-2018-09-21){ref-type="table-fn"}^                                                         .037                          .606
   pT1                                                           35 (16.9)                  172 (83.1)                        3 (18.8)   13 (81.3)   
   pT2                                                           10 (37.0)                  17 (63.0)                         2 (40.0)   3 (60.0)    
   pT3/4                                                         11 (16.7)                  55 (83.3)                         1 (20.0)   4 (80.0)    
  pN category^[a](#tfn2-jptm-2018-09-21){ref-type="table-fn"}^                                                         .899                          \> .999
   pN0                                                           55 (18.7)                  239 (81.3)                        6 (24.0)   19 (76.0)   
   pN1                                                           1 (16.7)                   5 (83.3)                          0          1 (100)     

Values are presented as number (%).

BAP1, BRCA1-associated protein 1; RCC, renal cell carcinoma; WHO, World Health Organization; ISUP, International Society of Urological Pathology.

AJCC eighth edition.

###### 

Univariate Cox regression analyses for cancer-specific survival and recurrence-free survival in patients with clear cell RCC

  Variable                Cancer-specific survival   Recurrence-free survival                                      
  ----------------------- -------------------------- -------------------------- --------- -------- --------------- ---------
  BAP1                                                                                                             
   Positive vs negative   1.076                      0.405--2.859               .884      1.125    0.462--2.740    .795
  Sex                                                                                                              
   Female vs male         2.140                      0.807--5.676               .118      1.879    0.814--4.334    .139
  WHO/ISUP grade                                                                                                   
   1--2                   1                                                               1                        
   3                      3.401                      1.138--10.165              .028      2.484    0.997--6.185    .051
   4                      20.883                     7.323--59.550              \< .001   16.202   6.749--38.890   \< .001
  Vascular invasion                                                                                                
   Absent vs present      9.386                      4.306--20.460              \< .001   8.219    4.130--16.355   \< .001
  Tumor necrosis                                                                                                   
   Absent vs present      18.216                     5.713--58.079              \< .001   16.980   5.953--48.428   \< .001
  Sarcomatoid feature                                                                                              
   Absent vs present      13.933                     6.283--30.896              \< .001   10.823   5.103--22.957   \< .001
  pT category                                                                                                      
   pT1                    1                                                               1                        
   pT2                    6.298                      1.409--28.145              .016      8.249    2.387--28.509   .001
   pT3 and pT4            18.200                     6.185--53.557              \< .001   18.733   7.103--49.404   \< .001
  Lymph node metastasis                                                                                            
   Absent vs present      32.885                     10.417--103.815            \< .001   18.940   6.203--57.828   \< .001

RCC, renal cell carcinoma; HR, hazard ratio; CI, confidence interval; BAP1, BRCA1-associated protein 1; WHO, World Health Organization; ISUP, International Society of Urological Pathology.
